Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Rotarix™ significantly reduced severe rotavirus gastroenteritis in African babies during their first year of life
NEJM today published the first study demonstrating that Rotarix, GSK rotavirus vaccine.
-
GSK announces ‘open innovation’ strategy to help deliver new and better medicines for people living in the world’s poorest countries
'Open Lab' established with $8m seed funding for new research
-
GSK contributes to Haiti relief efforts
In keeping with GSK's response to previous natural disasters, we have initiated a program of support for Haiti.
-
GSK exercises option to progress development of ChemoCentryx’s Traficet-EN for the treatment of inflammatory bowel diseases
GlaxoSmithKline(GSK) andChemoCentryx Inc. today announced that GSK has exercised its option to obtain an exclusive license.
-
Revolade (eltrombopag) receives positive opinion in Europe for chronic immune thrombocytopenic purpura
GSK announced today that CHMP has issued a positive opinion for Revolade.
-
GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
Next advance in the treatment of cold sores - Strengthens a key OTC franchise
-
GSK publishes speaking, consulting fees paid to US healthcare professionals
Company progresses commitments to increase transparency
-
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated.
-
GSK and Intercell form strategic alliance to develop and commercialise innovative needle-free patch-based vaccines
GlaxoSmithKline Biologicals SA (GSK) and Intercell today announced an agreement to form a strategic alliance to accelerate the development.
-
Pre-Budget Report response - GSK comments on patent box
GSK welcomes the introduction of a new measure announced in the Pre-Budget Report to stimulate future investment in the UK.
-
GSK initiates second pivotal Phase III trial for investigational cardiovascular medication Darapladib
GSK today announced initiation of the second large-scale Phase III clinical trial to evaluate long-term treatment.
-
GSK Update: GSK’s Arepanrix™ H1N1 pandemic vaccine prequalified by the World Health Organization
First prequalification for an H1N1 pandemic vaccine
-
GSK completes extension of strategic collaboration with Aspen
GSK announced that yesterday it completed the extension of its strategic relationship with Aspen Pharmacare Holdings Limited (Aspen)
-
GlaxoSmithKline announced as Tier 3 Sponsor as London 2012 anti-doping plans confirmed
GSK becomes Laboratory Services Provider
-
Regulatory Update: GSK files Rotarix for prevention of rotavirus in Japan
GlaxoSmithKline (GSK) announced today that it has filed its vaccine for the prevention of rotavirus gastroenteritis.
-
GlaxoSmithKline and Gilead announce agreement to commercialise Viread® for chronic hepatitis B in key Asian countries
GlaxoSmithKline (GSK) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced a licensing agreement to commercialise.
-
GSK Regulatory Update: Avodart
GSK expects to resubmit the file shortly. This action is not the result of new findings related to safety or efficacy.
-
Pandemic 2009 Influenza Update: Pandemrix™ data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline (GSK) today announced that over 40 million doses of its adjuvanted pandemic H1N1 vaccine have been distributed to countries.
-
GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addiction
GSK and Nabi announced an exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine.
-
Pandemic 2009 Influenza Update: US FDA approves GSK’s pandemic H1N1 vaccine
GSK today announced that FDA has approved a sBLA for its unadjuvanted influenza A (H1N1) pandemic vaccine.
